CLNN 250117 7.00C (CLNN250117C7000) Stock Options, News & Quotes

3.95
0.000.00%

15min DelayClose Jul 5 14:12 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Trytosaveabit

Dec 10, 2024 13:21

New 425B ( Prospectus )

$Clene (CLNN.US)$ (((((((. Clene Inc. has entered into an equity distribution agreement to offer and sell up to $7.39 million of common stock through Canaccord Genuity. The at-the-market offering will be used to fund clinical development of CNM-Au8, Clene's lead drug candidate for neurological disorders like ALS and MS.
The company recently received FDA guidance on a potential accelerated approval pathway for CNM-Au8 in ALS. Clene plans to provide additional biomark...

Trytosaveabit

Dec 10, 2024 07:34

News

$Clene (CLNN.US)$ Reuters
1 min ago
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional Cnm-AU8® Biomarker Data in ALS

Trytosaveabit

Nov 13, 2024 07:03

Hmm! Update

$Clene (CLNN.US)$ Clene Met With FDA on Nov 1 in Type C Meeting to Discuss Potential for Accelerated Approval Pathway in ALS >CLNN
Dow Jones· just

Trytosaveabit

Oct 23, 2024 07:34

Update

$Clene (CLNN.US)$ Clene Inc. unveiled the preliminary design for RESTORE-ALS, a significant Phase 3 clinical trial of their CNM-Au8 30 mg treatment, at the 2024 NEALS Meeting. This development marks a pivotal moment in their research efforts, aiming to bring new treatment options for ALS patients. Investors and market enthusiasts may find this an exciting opportunity as the company progresses in its groundbreaking trial.

soyabean89

Oct 11, 2024 09:34

$Clene (CLNN.US)$ wonder it will punch above cloud...dam...

Share Your Profit/Loss